Reviewing therapy with radioisotopes for pain bone metastasis and its possible evolution
DOI:
https://doi.org/10.15392/bjrs.v10i2.2011Keywords:
Radiopharmaceuticals. Radioisotope. Metastasis. BoneAbstract
Introduction: The therapy with radioisotopes is widely used, its beginnings were focused on thyroid pathologies treatments. Over the years, the radiopharmaceuticals and/or radioisotopes have had their usage increased, to be used on painful bone metastasis. Material and Methods: A bibliographic search was conducted in the major health Science basis to evaluate what the therapies have to offer for patients in this condition. Results: Currently there are only two available materials in Brazil, the Sm153 that is national production, and Ra223, that is imported. Outside Brazil we can find a variety of materials that have already been approved by the Sanitary Organization in other countries, even though we are not authorized to use them due to Brazilian Regulation and production issues. Conclusion: Besides the diversity of materials that could be used, dosimetry systems must be implemented in order to have a more efficient treatment and to have an accurate administrated activities to patients.
- Views: 166
- PDF Downloads: 135
- XML Downloads: 20
Downloads
References
V. Ralph McCready. Radioiodine – the success story of Nuclear Medicine. Eur J Nucl Med Mol Imaging (2017) 44:179–182 DOI: https://doi.org/10.1007/s00259-016-3548-5
Luis Costa & Xavier Badia & Edward Chow et all. Impact of skeletal complications on patients’ quality of life, mobility, and functional Independence. Support Care Cancer (2008) 16:879–889 DOI: https://doi.org/10.1007/s00520-008-0418-0
Narendra Nair, Relative Efficacy of 32P and 89Sr in Palliation in Skeletal Metastases. J NucI Med1999.40:256 a 261
Neeta Pandit-Taskar, Steven M. Larson et all, Bone-Seeking Radiopharmaceuticals for Treatment of Osseous Metastases, Part 1: Therapy with 223Ra-Dichloride. J Nucl Med 2014; 55:268–274 DOI: https://doi.org/10.2967/jnumed.112.112482
Hélène Kolesnikov-Gauthier, Nathalie Lemoine, Emmanuelle Tresch-Bruneel et all. Efficacy and safety of 153Sm-EDTMP as treatment of painful bone metastasis: a large single-center study. Support Care Cancer DOI 10.1007/s00520-017-3885-3.
Ajit S. Shinto, Madhava B. Mallia, Mythili Kameswaran, et all. Clinical utility of 188Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies. World J Nucl Med. 2018 Oct-Dec; 17(4): 228–235. DOI: https://doi.org/10.4103/wjnm.WJNM_68_17
Jörgen Elgqvist,SofiaFrost, Jean-Pierre Pouget,PerAlbertsson. The potential and hurdles of targeted alpha therapy – clinical trials and beyond. Frontiers in Oncology January 2014 | Volume 3 | Article 324 DOI: https://doi.org/10.3389/fonc.2013.00324
Mareike Roscher , Gábor Bakos and Martina Benešová. Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management. Pharmaceuticals 2020, 13, 76.
G.B. Saha, Fundamentals of Nuclear Pharmacy, Springer International Publishing AG 2018 (paperback). DOI: https://doi.org/10.1007/978-3-319-57580-3
Ballinger JR. Theranostic radiopharmaceuticals: established agents in current use. Br J Radiol 2018; 91 DOI: https://doi.org/10.1259/bjr.20170969
Maria E. Lyra, Maria Andreou, Antonios Georgantzoglou et all. Radionuclides Used in Nuclear Medicine Therapy – From Production to Dosimetry. Current Medical Imaging Reviews, 2013, 9, 51-75 51. DOI: https://doi.org/10.2174/1573405611309010008
Hojjat Ahmadzadehfar, MD, MSc , Markus Essler, MD , Kambiz Rahbar, MD , et all Radionuclide Therapy for bone metastases utility of scintigraphy and PET imaging for treatment planning. PET Clin. 2018; 13:491–503). DOI: https://doi.org/10.1016/j.cpet.2018.05.005
Joon Young Choi. Treatment of Bone Metastasis with Bone-Targeting Radiopharmaceuticals. Nuclear Medicine and Molecular Imaging (2018) 52:200–207 DOI: https://doi.org/10.1007/s13139-017-0509-2
George Sgouros , Lisa Bodei , Michael R. McDevitt et all. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 19, 819 (2020) DOI: https://doi.org/10.1038/s41573-020-0085-5
Mareike Roscher, Gábor Bakos, Martina Benešová. Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management. Pharmaceuticals 020, 13, 76; DOI: https://doi.org/10.3390/ph13040076
Stephen A. Graves, PhD, and Robert F. Hobbs, PhD. Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy. Semin Radiat Oncol 31:37−44.2020 DOI: https://doi.org/10.1016/j.semradonc.2020.07.008
Ashutosh Dash, Tapas Das, and Furn F. (Russ) Knapp Jr. Targeted Radionuclide Therapy of Painful Bone Metastases: Past De- velopments, Current Status, Recent Advances and Future Directions. Current Medicinal Chemistry, 2020, 27, 3187-3249 DOI: https://doi.org/10.2174/0929867326666190201142814
Diretrizes básicas de proteção radiológica. Norma CNENNN3.01 Resolução 164/14Março/2014
Requisitos de segurança e proteção radiológica para serviços de medicina nuclear. Norma CNEN NN 3.05 Resolução CNEN 159/13 dez./2013
Resolução-RDC No 64, de 18 de dezembro de 2009. ANVISA
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Radiation Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
